دورية أكاديمية
أعرض في EDS

New proteasome inhibitors in the treatment of multiple myeloma.

التفاصيل البيبلوغرافية
العنوان: New proteasome inhibitors in the treatment of multiple myeloma.
المؤلفون: Hungria VTM; Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, SP, Brazil. Electronic address: hungria@dialdata.com.br., Crusoé EQ; Universidade Federal da Bahia, Hospital Universitário Professor Edgar Santos, Serviço de Hematologia, Salvador, BA, Brazil., Bittencourt RI; Hospital de Clínicas de Porto Alegre, Serviço de Hematologia, Porto Alegre, RS, Brazil., Maiolino A; Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil., Magalhães RJP; Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil., Sobrinho JDN; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., Pinto JV; Universidade Católica de Brasília, Brasília, DF, Brazil., Fortes RC; Evidências - Kantar Health, São Paulo, SP, Brazil., Moreira ES; Evidências - Kantar Health, São Paulo, SP, Brazil., Tanaka PY; Takeda Pharma, São Paulo, SP, Brazil.
المصدر: Hematology, transfusion and cell therapy [Hematol Transfus Cell Ther] 2019 Jan-Mar; Vol. 41 (1), pp. 76-83. Date of Electronic Publication: 2018 Oct 15.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Elsevier Editora Ltda Country of Publication: Brazil NLM ID: 101725732 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2531-1387 (Electronic) Linking ISSN: 25311379 NLM ISO Abbreviation: Hematol Transfus Cell Ther Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Rio de Janeiro, Brazil] : Elsevier Editora Ltda, [2018]-
مستخلص: The treatment of patients with relapsed and/or refractory multiple myeloma has improved considerably in the last 15 years, after the introduction of proteasome inhibitors and immunomodulatory drugs. The first clinical trials with new proteasome inhibitors have produced exciting results, particularly those comparing triplet regimens with standard doublet regimens, with a gain in progression-free survival accompanied by an acceptable safety profile and either similar or better health-related quality of life. New proteasome inhibitors hold the potential to fill unmet needs in multiple myeloma management regarding improvement of clinical outcomes, including delayed progression of disease in high-risk patients. This review summarizes the main pharmacological properties and clinical outcomes of these agents, and discusses their potential to change the whole multiple myeloma therapeutic landscape.
References: Nat Rev Clin Oncol. 2017 Jul;14(7):417-433. (PMID: 28117417)
J Cell Mol Med. 2014 Jun;18(6):947-61. (PMID: 24712303)
Br J Haematol. 2017 Oct;179(2):198-218. (PMID: 28556890)
Clin Cancer Res. 2012 Jan 1;18(1):15-20. (PMID: 22019514)
Eur J Haematol. 2016 Nov;97(5):416-429. (PMID: 27528496)
Am Soc Clin Oncol Educ Book. 2015;:e504-11. (PMID: 25993216)
Lancet Oncol. 2016 Jan;17(1):27-38. (PMID: 26671818)
Eur J Haematol. 2016 Jun;96(6):564-77. (PMID: 26893241)
Blood Cancer J. 2016 Jan 15;6:e384. (PMID: 26771810)
J Hematol Oncol. 2016 Jun 30;9(1):52. (PMID: 27363832)
Blood Adv. 2017 Feb 27;1(7):449-454. (PMID: 29296960)
Leuk Res. 2014 Jan;38(1):1-9. (PMID: 24239172)
Lancet. 2017 Feb 4;389(10068):519-527. (PMID: 28017406)
Nat Rev Clin Oncol. 2017 Feb;14(2):100-113. (PMID: 27531699)
Am J Pathol. 2010 Jun;176(6):2658-68. (PMID: 20519734)
J Hematol Oncol. 2017 Jul 6;10(1):137. (PMID: 28683766)
J Card Fail. 2015 Feb;21(2):138-44. (PMID: 25433360)
Mol Cancer Ther. 2013 Jun;12(6):831-43. (PMID: 23729400)
J Immunol Res. 2015;2015:541984. (PMID: 26636107)
J Clin Oncol. 2012 Jul 10;30(20):2475-82. (PMID: 22585692)
Ann Hematol. 2017 Jan;96(1):65-72. (PMID: 27815724)
Leukemia. 2017 Jan;31(1):107-114. (PMID: 27416912)
Anticancer Drugs. 2017 Jul;28(6):660-668. (PMID: 28430745)
Blood. 2017 Sep 28;130(13):1507-1513. (PMID: 28747306)
Blood. 2012 Oct 4;120(14):2817-25. (PMID: 22833546)
Lancet. 2010 Dec 18;376(9758):2075-85. (PMID: 21146205)
N Engl J Med. 2008 Aug 28;359(9):906-17. (PMID: 18753647)
Nat Rev Dis Primers. 2017 Jul 20;3:17046. (PMID: 28726797)
Lancet Oncol. 2017 Oct;18(10):1327-1337. (PMID: 28843768)
Leukemia. 2016 May;30(5):1005-17. (PMID: 26710887)
Oncotarget. 2017 Jul 15;8(36):60656-60672. (PMID: 28948001)
Ther Adv Hematol. 2017 Jul;8(7):209-220. (PMID: 28694935)
N Engl J Med. 2016 Apr 28;374(17):1621-34. (PMID: 27119237)
J Clin Oncol. 2013 Sep 10;31(26):3279-87. (PMID: 23897961)
Blood. 2016 Jun 30;127(26):3360-8. (PMID: 27207788)
Curr Cancer Drug Targets. 2014;14(6):517-36. (PMID: 25092212)
Pharmaceuticals (Basel). 2017 Apr 11;10(2):. (PMID: 28398261)
Blood. 2012 Aug 23;120(8):1589-96. (PMID: 22791289)
Cancer Res. 2010 Mar 1;70(5):1970-80. (PMID: 20160034)
J Blood Med. 2017 Aug 22;8:107-121. (PMID: 28860887)
Haematologica. 2017 Oct;102(10):1767-1775. (PMID: 28751562)
J Clin Oncol. 2019 Aug 1;37(22):1946-1955. (PMID: 31188726)
Br J Haematol. 2015 Dec;171(5):798-812. (PMID: 26456076)
CA Cancer J Clin. 2017 Jan;67(1):7-30. (PMID: 28055103)
Haematologica. 2008 May;93(5):791-2. (PMID: 18450738)
Semin Oncol Nurs. 2017 Aug;33(3):279-291. (PMID: 28666621)
Cancer Manag Res. 2017 Jul 10;9:287-298. (PMID: 28744159)
Mayo Clin Proc. 2016 Jan;91(1):101-19. (PMID: 26763514)
N Engl J Med. 2015 Jan 8;372(2):142-52. (PMID: 25482145)
فهرسة مساهمة: Keywords: Bortezomib; Carfilzomib; Ixazomib; Multiple myeloma; Proteasome inhibitors
تواريخ الأحداث: Date Created: 20190223 Latest Revision: 20231005
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC6371737
DOI: 10.1016/j.htct.2018.07.003
PMID: 30793108
قاعدة البيانات: MEDLINE
الوصف
تدمد:2531-1387
DOI:10.1016/j.htct.2018.07.003